Can we obtain prognostic information from healthy tissue uptake and volume in baseline 18F-FDG PET/CT imaging in diffuse large B-cell lymphoma?
European Journal of Nuclear Medicine and Molecular Imaging · 2026
DOI: 10.1007/s00259-025-07503-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Nienke R Gerards und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherl…. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Lymphoma, Large B-Cell, Diffuse. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: KWF Kankerbestrijding.
Abstract (Originalsprache)
Purpose
Diffuse large B-cell lymphoma (DLBCL) patients often experience relapse or progression after treatment, emphasizing the need for better prognostic markers. This study investigated baseline FDG uptake and volume of healthy tissues and tumours, to assess their association with time-to-progression (TTP) in DLBCL.
Methods
This study included 259 newly diagnosed DLBCL patients. Outcome was two-year TTP after treatment initiation. Automatic segmentation of tissues was performed on the low dose CT scans. Tumour lesions were outlined with a semi-automated segmentation method (standardised uptake value ≥ 4) and subtracted from the tissues. Mean standardised uptake value (SUVmean), tissue-to-blood SUVmean ratio, volume, and total lesion glycolysis (TLG) were determined for the spleen, liver, kidneys, lungs, and brain. Only SUVmean and SUVmean ratio were assessed for fat, bone, and skeletal muscle. Intercorrelations among all tissues and correlations with tumour TLG were calculated. Volume and uptake measures were compared between patients with and without progression using the Wilcoxon signed-rank test. Any measure significantly associated with two-year TTP was added to an existing logistic regression model based on baseline tumour characteristics to assess its added prognostic value.
Results
Patients with progression showed a significantly higher spleen-to-blood SUVmean ratio, lower SUVmean and TLG in the brain, lower SUVmean in skeletal muscle, and a larger liver volume. Liver volume and spleen-to-blood SUVmean ratio did not significantly improve the prediction of two-year TTP compared to the original model only based on tumour characteristics.
Conclusion
Healthy tissue PET/CT measures were significantly associated with two-year TTP in DLBCL patients. However, these measures did not improve the prediction of two-year TTP compared to models using only tumour characteristics. Trial registration number and date of registration HOVON-84: EudraCT: 2006-005, 174 − 42, retrospectively registered 01-08-2008.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands. n.r.gerards@amsterdamumc.nl.
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands. n.r.gerards@amsterdamumc.nl.
- Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
- Department of Haematology, Amsterdam UMC location Vrije Universiteit Amsterdam, Boelelaan 1117, Amsterdam, The Netherlands.
- Department of Haematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
- Department of Radiology and Nuclear Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
ORCID-Profile: Nienke R Gerards, Sanne E Wiegers, Jakoba J Eertink, Pieternella J Lugtenburg, Josée M Zijlstra, Ronald Boellaard, Gerben J C Zwezerijnen
Förderung
- KWF Kankerbestrijding
Zitieren
APA
Gerards, N. R., Wiegers, S. E., Bes, A. L., Eertink, J. J., Lugtenburg, P. J., Zijlstra, J. M., Boellaard, R., & Zwezerijnen, G. J. C. (2026). Can we obtain prognostic information from healthy tissue uptake and volume in baseline 18F-FDG PET/CT imaging in diffuse large B-cell lymphoma?. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07503-9
Vancouver
Gerards NR, Wiegers SE, Bes AL, Eertink JJ, Lugtenburg PJ, Zijlstra JM, et al. Can we obtain prognostic information from healthy tissue uptake and volume in baseline 18F-FDG PET/CT imaging in diffuse large B-cell lymphoma?. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-025-07503-9
BibTeX
@article{Gerards2026,
author = {Gerards, Nienke R and Wiegers, Sanne E and Bes, Anne L and Eertink, Jakoba J and Lugtenburg, Pieternella J and Zijlstra, Josée M and Boellaard, Ronald and Zwezerijnen, Gerben J C},
title = {Can we obtain prognostic information from healthy tissue uptake and volume in baseline 18F-FDG PET/CT imaging in diffuse large B-cell lymphoma?},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2026},
doi = {10.1007/s00259-025-07503-9}
}
EUVIMED